Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer

PHASE2

Phase

TERMINATED

Status

Enrollment

OTHER

Sponsor class

Stopped Data Safety Monitoring Board is in agreement with the study findings so far and the stopping rule has been met, which suspends the study treatment arms in March 2021.

Conditions

Locally Advanced Breast Cancer

Interventions

DRUG: Docetaxel
DRUG: Carboplatin
DRUG: Trastuzumab
DRUG: Pertuzumab
DRUG: Pegfilgrastim
DRUG: Trastuzumab
DRUG: Paclitaxel
DRUG: Doxorubicin
DRUG: Cyclophosphamide
DRUG: Paclitaxel

Sponsor

Icahn School of Medicine at Mount Sinai